The Eli Lilly-backed liver disease drug developer floated at the top of its range to raise almost $128m, following $207m of venture funding.

Eli Lilly and WuXi AppTec scored exits from the immunotherapy developer, which has seen its shares rocket 66% since it floated.

The Novo, Pfizer and Nan Fung-backed oncology therapy developer priced an upsized offering above its range and is now valued above $1bn.

Alphabet and Ping An are in line for exits after the online health insurer filed to float on the New York Stock Exchange.

SoftBank's Vision Fund is reportedly urging some of its larger portfolio companies to seek initial public offerings during a bull market.

Stanford spinout Bolt Biotherapeutics has raised more than twice as much as originally planned in an offering that also provided exits for corporates Pfizer, Novo and Fan Fung.

Immunocore has raised more than $258m in an upsized offering and an additional $15m in a concurrent private placement.

Merck & Co and UnitedHealth Group are set to exit the urologic cancer diagnostics technology provider in an acquisition by Veracyte.

The Cambrian Biopharma-backed cancer treatment developer floated above its range in an offering on the Nasdaq Global Market.

The Tencent and Baidu-backed livestreaming app saw its shares almost triple on the first day of trading and is now valued at about $160bn.